Macular degeneration—both age-related (AMD) and inherited forms—involves progressive death of photoreceptor cells (rods and cones) in the central retina.
Macular degeneration—both age-related (AMD) and inherited forms—involves progressive death of photoreceptor cells (rods and cones) in the central retina. In AMD, a combination of lipid accumulation (drusen), oxidative stress, and chronic inflammation triggers degeneration of the retinal pigment epithelium (RPE), the supportive layer feeding photoreceptors. In inherited retinal dystrophies, genetic mutations directly compromise photoreceptor function or survival. Cell therapy approaches aim to replace lost photoreceptors or RPE cells using fetal-stage stem cells, placental MSCs, or induced pluripotent stem cell (iPSC)-derived retinal cells. These cell types can differentiate into photoreceptors or RPE in controlled environments. The proposed mechanism involves transplantation of functional cells into the macula, where they integrate into damaged retinal circuits and restore light sensitivity and signal transmission to the brain.
| עלות מעריכה · בולגריה (EU) | €3,000–€8,000 |
|---|---|
| טווח עלויות השוק הגלובלי | €9,200–€27,600 (stemconnect.io) |
| סוגי התאים העיקריים שנחקרו | Fetal Stem Cells, MSCs from Amniotic Membrane |
| סטטוס אישור | ניסיוני |
| ניסויים רשומים (ClinicalTrials.gov) | 44 · 8 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Forty-four completed or ongoing clinical trials in macular degeneration and inherited retinal diseases employ cell-based approaches, with 8 active trials enrolling. Early human trials have used fetal retinal tissue, placental MSCs, and more recently iPSC-derived photoreceptor precursors and RPE cells. Safety data are emerging—transplanted cells are generally tolerated, with few reports of immune rejection or severe inflammation. Functional improvements (visual acuity, light sensitivity, visual fields) have been measured in small cohorts, showing stabilisation of vision loss in some participants and modest gains in best-corrected acuity in others (typically ≤3 lines on an eye-chart). No large phase III trial has yet demonstrated a definitive vision-restoration threshold.
Depending on assessment, a Macular Degeneration & Vision protocol may draw on:
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Macular Degeneration & Vision cost-by-country breakdown, or compare the best countries for Macular Degeneration & Vision →
Before booking, check safety & regulation, the recovery climate, אם אתה עשוי להיות מועמד, and which cell type fits Macular Degeneration & Vision.
שאלות תשובות דגנרציה מקולרית וכישלון ראייה מלאות → · פירוט עלויות דגנרציה מקולרית וכישלון ראייה →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: האם אני מועמד? · איזה סוג תאים? · Types of clinics & best countries · מחשבון עלויות
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם